Related names and biological pathways do not make products interchangeable. A regulatory decision concerns a defined medicine and use. It does not automatically extend to a different peptide because both interact with melanocortin receptors or appear together in an online guide.
The current FDA safety page identifies concerns about melanotan II, including peptide-related impurities and immune responses. The entry appears in the table of nominated substances whose nominations were withdrawn. That administrative location should be reported accurately; it is not an approval and should not be described as one.
The Australian TGA warning states that melanotan tanning products are not approved there as tanning agents. It also warns about uncertain product contents. This is jurisdiction-specific regulatory information, not a claim that all medicines involving related pathways have the same status worldwide.
The distinction becomes important when a claim moves from “this family includes an approved medicine” to “therefore this vial is medically validated.” Several missing links remain: chemical identity, formulation, manufacturing controls, clinical indication and evidence for the actual product. A shared word in the name answers none of those questions.
Likewise, a research label does not solve the problem. It can describe an intended laboratory context, but it does not supply clinical evidence or establish suitability for administration to people. A licensed product's research does not establish equivalence with an unrelated item.
For someone considering treatment for a medical concern, a clinician should evaluate that concern using established options and the relevant jurisdiction's current records. Cosmetic tanning is a different objective from treating a defined disease. No home-use regimen follows from the existence of a related pharmaceutical product.
The useful rule is to keep identity and authorization together. Ask which exact substance, which product, which indication and which regulator are being discussed. If the evidence changes subject midway through the answer, it has not established what the reader originally wanted to know.